Clinical Trials
2
Active:1
Completed:1
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide
Phase 2
Completed
- Conditions
- Immune System DiseasesChronic Graft-Versus-Host Disease
- Interventions
- First Posted Date
- 2016-11-17
- Last Posted Date
- 2022-05-09
- Lead Sponsor
- Medsenic
- Target Recruit Count
- 21
- Registration Number
- NCT02966301
News
BioSenic Advances Autoimmune Pipeline and Explores Strategic M&A Opportunities
BioSenic is actively pursuing strategic mergers and acquisitions to expand its asset portfolio, focusing on opportunities within the biopharmaceutical sector.